Abingworth

General contacts
Investor type

PE / VC

Founded

1987

AUM

$1 288 M

Location

London, England, United Kingdom

Investment Ticket

$10-50 m

Investment Stage

Series B Series A Seed Late Stage (Series C+)

Region of investment

North America Europe
Investor profile last updated: 16 August, 2026

Profile

Abingworth is a life sciences investor based in London, New York, and San Francisco, founded in the 1980s. With a long history in biotech investing, the firm has expanded transatlantically, supporting over 200 companies with their team of 28 professionals. Known for their experience in navigating startups through various challenges, Abingworth takes pride in their strategic support to portfolio companies through unique approaches such as Venture Investments in Public Equities (VIPEs) and Clinical Co-Development.

Abingworth invests in life sciences and healthcare sectors, focusing on biotechnology and pharmaceuticals. They participate in seed, early, and development-stage funding, with investments primarily in North America and Europe. The firm manages multiple funds including Abingworth Bioventures funds and Clinical Co-Development funds, with recent fundraises totaling over $1 billion. Abingworth's presence in key biotech hubs enables direct interaction with talented entrepreneurs.

Noteworthy portfolio companies include Prism - precision medicine, F2G - antifungal treatments, GammaDelta - oncology therapies, and Inflazome - inflammasome inhibitors. Abingworth has a record of taking companies through IPOs and strategic transactions, utilizing their deep life sciences expertise.

Industry

Pharmaceuticals Medical Devices Biotechnology Healthcare Services HealthTech Software AI MedTech Technology Life Sciences Machine Learning (ML) Fintech

Abingworth Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region 		Size AUM Launch date
Abingworth Clinical Co-Development Fund
Venture Capital (VC)
Biotechnology
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$105 M
January 2016
Fund VII
Venture Capital (VC)
Healthcare Services
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$220 M
August 2017
Abingworth Bioventures VII
Venture Capital (VC)
Biotechnology
Healthcare Services
Pharmaceuticals
Life Sciences
Seed
Series A
North America
Europe
$5-10 m
$315 M
July 2018
Abingworth Bioventures VIII
Venture Capital (VC)
Biotechnology
Healthcare Services
Pharmaceuticals
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$465 M
February 2021
Abingworth Clinical Co-Development Co-Investment Fund
Venture Capital (VC)
Biotechnology
Fintech
Healthcare Services
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$356 M
October 2023

Contacts

Name
Title
Email
Social Networks
avatar
Bali Muralidhar Managing Partner, Chief Investment Officer
Managing Partner, Chief Investment Officer
b•••@•••
LinkedIn
avatar
Kurt von Emster Managing Partner
Managing Partner
g•••@•••
Upgrade to see contacts
avatar
8TUm9OAkvyIVCpHD 8TUm9OAkvyIVCpHD
8TUm9OAkvyIVCpHD
[email protected]
linkedin twitter
avatar
8TUm9OAkvyIVCpHD 8TUm9OAkvyIVCpHD
8TUm9OAkvyIVCpHD
[email protected]
linkedin twitter
avatar
8TUm9OAkvyIVCpHD 8TUm9OAkvyIVCpHD
8TUm9OAkvyIVCpHD
[email protected]
linkedin twitter
Investment-team contacts for Abingworth — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Abingworth

Abingworth is a venture capital and private equity firm. It backs companies at Series B, Series A, Seed and Late Stage (Series C+), writing tickets of $10-50 m.
Abingworth is located in London, England, United Kingdom.
Abingworth was founded in 1987.
Abingworth invests in companies and startups in Pharmaceuticals, Medical Devices, Biotechnology, Healthcare Services, HealthTech, Software, AI, MedTech, Technology, Life Sciences, Machine Learning (ML), Fintech.
Abingworth invests in companies and startups in North America, Europe.
Abingworth invests in companies and startups at Series B, Series A, Seed, Late Stage (Series C+).
Abingworth usually invests $10-50 m on average.
Abingworth has around $1 288m assets under management.
Abingworth last fund was created/launched in 2023-10-23
Abingworth can be reached through its website abingworth.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Abingworth — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Abingworth directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.